[go: up one dir, main page]

TN2009000138A1 - Biaryl-ether-urees - Google Patents

Biaryl-ether-urees

Info

Publication number
TN2009000138A1
TN2009000138A1 TNP2009000138A TN2009000138A TN2009000138A1 TN 2009000138 A1 TN2009000138 A1 TN 2009000138A1 TN P2009000138 A TNP2009000138 A TN P2009000138A TN 2009000138 A TN2009000138 A TN 2009000138A TN 2009000138 A1 TN2009000138 A1 TN 2009000138A1
Authority
TN
Tunisia
Prior art keywords
compounds
biaryl
urea
ether
preparation
Prior art date
Application number
TNP2009000138A
Other languages
English (en)
Inventor
Lorraine Kathleen Fay
Douglas Scott Johnson
Scott Edward Lazerwith
Mark Anthony Morris
Lijuan Jane Wang
Marvin Jay Meyers
Suzanne Ross Kesten
Cory Michael Stiff
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39314409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000138(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TN2009000138A1 publication Critical patent/TN2009000138A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne les composés de formule (I) ou un de leurs sels pharmaceutiquement acceptables, des procédés pour la préparation des composés, les intermédiaires utilisés dans la préparation des composés ; des compositions contenant les composés et des utilisations des composés dans le traitement de maladies ou d'affections associées à une activité d' hydrolase d'amide d'acide gras (FAAH).
TNP2009000138A 2006-10-18 2009-04-14 Biaryl-ether-urees TN2009000138A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82996606P 2006-10-18 2006-10-18
US96521007P 2007-08-17 2007-08-17
PCT/IB2007/003202 WO2008047229A2 (fr) 2006-10-18 2007-10-05 Composés d'urée de bisaryle éther

Publications (1)

Publication Number Publication Date
TN2009000138A1 true TN2009000138A1 (fr) 2010-10-18

Family

ID=39314409

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000138A TN2009000138A1 (fr) 2006-10-18 2009-04-14 Biaryl-ether-urees

Country Status (38)

Country Link
US (1) US8044052B2 (fr)
EP (1) EP2076508B1 (fr)
JP (1) JP4434313B2 (fr)
KR (1) KR101181194B1 (fr)
CN (1) CN101595102B (fr)
AP (1) AP2780A (fr)
AR (1) AR063331A1 (fr)
AT (1) ATE493984T1 (fr)
AU (1) AU2007311591B2 (fr)
BR (1) BRPI0717596B8 (fr)
CA (1) CA2663984C (fr)
CL (1) CL2007003000A1 (fr)
CR (2) CR10701A (fr)
CY (1) CY1111170T1 (fr)
DE (1) DE602007011793D1 (fr)
DK (1) DK2076508T3 (fr)
EA (1) EA015488B1 (fr)
ES (1) ES2357340T3 (fr)
GE (1) GEP20125425B (fr)
HN (1) HN2007000407A (fr)
HR (1) HRP20110158T1 (fr)
IL (1) IL197664A (fr)
MA (1) MA30801B1 (fr)
ME (1) ME01308B (fr)
MX (1) MX2009004233A (fr)
MY (1) MY145460A (fr)
NO (1) NO342266B1 (fr)
NZ (1) NZ575624A (fr)
PE (1) PE20081265A1 (fr)
PL (1) PL2076508T3 (fr)
PT (1) PT2076508E (fr)
RS (2) RS20090154A (fr)
SI (1) SI2076508T1 (fr)
TN (1) TN2009000138A1 (fr)
TW (1) TWI404715B (fr)
UY (1) UY30649A1 (fr)
WO (1) WO2008047229A2 (fr)
ZA (1) ZA200902548B (fr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2937341B1 (fr) 2004-12-30 2017-07-05 Janssen Pharmaceutica N.V. Dérivés d'phénylamides de 4-(benzyl)-pipérazine-1-acide carboxylique et composés similaires en tant que modulateurs de l'hydrolase des amides d'acides gras (faah) pour le traitement de l'anxiété, de la douleur et d'autres états
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
RS20090154A (sr) 2006-10-18 2010-10-31 Pfizer Products Inc. Jedinjenja biaril etra uree
JP5637982B2 (ja) 2008-04-09 2014-12-10 インフィニティー ファーマシューティカルズ， インコーポレイテッド 脂肪酸アミド加水分解酵素の阻害剤
US20110053950A1 (en) * 2008-04-17 2011-03-03 Pfizer, Inc. 4-benzylidene-3-methylpiperidine aryl carboxamide compounds useful as faah inhibitors
CA2717087A1 (fr) * 2008-04-17 2009-10-22 Pfizer Inc. Carboxamides d'aryle a 5 atomes de type 4-[3-(aryloxy)benzylidene]-3-methylpiperidine
JP2011518143A (ja) * 2008-04-17 2011-06-23 ファイザー・インク Ｆａａｈ阻害剤として有用なエーテルベンジリデンピペリジンアリールカルボキサミド化合物
CA2719784A1 (fr) * 2008-04-17 2009-10-22 Pfizer Inc. Composes d'ether-benzylidene-piperidine-aryl a 5 chainons-carboxamide utiles comme inhibiteurs de faah
WO2009127949A1 (fr) * 2008-04-17 2009-10-22 Pfizer Inc. Composés aryl carboxamides de 4-[3-(aryloxy)benzylidène]-3-méthyl pipéridine utiles comme inhibiteurs de la faah
US8461159B2 (en) 2008-11-25 2013-06-11 Jannsen Pharmaceutica BV Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
WO2010068452A1 (fr) 2008-11-25 2010-06-17 Janssen Pharmaceutica Nv Modulateurs à base d’urée à substitution hétéroaryle d'amide d’acide gras hydrolase
WO2010064597A1 (fr) * 2008-12-01 2010-06-10 武田薬品工業株式会社 Dérivé de pipéridine
PT2385938E (pt) 2009-01-12 2015-06-02 Pfizer Ltd Derivados de sulfonamida
JP2012523425A (ja) 2009-04-07 2012-10-04 インフイニトイ プハルマセウトイカルス インコーポレイテッド 脂肪酸アミドヒドロラーゼの阻害薬
WO2010118155A1 (fr) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibiteurs d'amide d'hydrolase d'acide gras
WO2010124113A1 (fr) 2009-04-23 2010-10-28 Infinity Pharmaceuticals, Inc. Anticorps anti-acide gras amide hydrolase 2 et leurs utilisations
US8927551B2 (en) 2009-05-18 2015-01-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US8765735B2 (en) 2009-05-18 2014-07-01 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US9149465B2 (en) 2009-05-18 2015-10-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
WO2010141817A1 (fr) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Modulateurs d'amide d'acide gras hydrolase de type diamine urée spirocyclique substituée par un groupe hétéroaryle
WO2010141809A1 (fr) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Modulateurs heterocycliques a base d'uree a substitution aryle de l'hydrolase des amides d'acides gras (faah)
CN102656172B (zh) 2009-09-09 2016-03-23 大日本住友制药株式会社 8-氧代二氢嘌呤衍生物
WO2011077313A1 (fr) 2009-12-22 2011-06-30 Pfizer Inc. Pipéridinecarboxamides en tant qu'inhibiteurs de mpges - 1
WO2011085216A2 (fr) 2010-01-08 2011-07-14 Ironwood Pharmaceuticals, Inc. Utilisation d'inhibiteurs de faah pour traiter la maladie de parkinson et le syndrome des jambes sans repos
CN102834401B (zh) 2010-02-03 2016-08-24 无限药品股份有限公司 脂肪酸酰胺水解酶抑制剂
EP2539358A1 (fr) 2010-02-25 2013-01-02 Pfizer Limited Analogues peptidiques
WO2011123719A2 (fr) 2010-03-31 2011-10-06 Ironwood Pharmaceuticals, Inc. Utilisation d'inhibiteurs de faah pour le traitement des douleurs abdominales, viscérales et pelviennes
UA108233C2 (uk) 2010-05-03 2015-04-10 Модулятори активності гідролази амідів жирних кислот
WO2012004714A2 (fr) 2010-07-09 2012-01-12 Pfizer Limited Composés chimiques
CA2804593C (fr) 2010-07-09 2015-11-24 Pfizer Limited Derives de biphenyloxybenzensulphonamide utiles en tant qu'inhibiteurs du canal sodique
US8772343B2 (en) 2010-07-12 2014-07-08 Pfizer Limited Chemical compounds
WO2012007861A1 (fr) 2010-07-12 2012-01-19 Pfizer Limited Dérivés de n-sulfonylbenzamide utiles comme inhibiteurs du canal sodique voltage-dépendant
EP2593428B1 (fr) 2010-07-12 2014-11-19 Pfizer Limited N-sulfonylbenzamides comme inhibiteurs des canaux sodiques voltage-dépendant
CA2800971A1 (fr) 2010-07-12 2012-01-19 Pfizer Limited Composes chimiques
CA2804877A1 (fr) 2010-07-12 2012-01-19 Pfizer Limited Composes chimiques
WO2012095781A1 (fr) 2011-01-13 2012-07-19 Pfizer Limited Dérivés d'indazole comme inhibiteurs des canaux sodiques
MA35024B1 (fr) 2011-04-05 2014-04-03 Pfizer Ltd Dérivés de pyrrolo-[2,3-d]pyrimidine servant d'inhibiteurs des kinases apparentés à la tropomyosine
ES2564366T3 (es) 2011-07-13 2016-03-22 Pfizer Limited Análogos de encefalina
WO2013042139A1 (fr) * 2011-09-23 2013-03-28 Advinus Therapeutics Limited Composés amides, compositions et applications de ceux-ci
WO2013054185A1 (fr) 2011-10-13 2013-04-18 Pfizer, Inc. Dérivés de pyrimidine et de pyridine utiles en thérapie
KR101586966B1 (ko) 2011-10-26 2016-01-19 화이자 리미티드 나트륨 채널 조절제로서 유용한 (4-페닐이미다졸-2-일) 에틸아민 유도체
JP6158817B2 (ja) 2011-10-28 2017-07-05 インヒビタクシン リミテッド 治療に有用なピリダジン誘導体
CA2857603C (fr) 2011-12-15 2016-08-02 Pfizer Limited Derives de sulfonamide
WO2013093688A1 (fr) 2011-12-19 2013-06-27 Pfizer Limited Dérivés sulfonamides et leur utilisation en tant qu'inhibiteurs de vgsc
JP6067031B2 (ja) 2012-01-04 2017-01-25 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ Ｎ−アミノスルホニルベンズアミド
EP2809655B1 (fr) 2012-02-03 2015-08-12 Pfizer Inc Dérivés d'imidazopyridine et de benziimidazole en tant que modulateurs du canal sodium
WO2014053965A1 (fr) 2012-10-04 2014-04-10 Pfizer Limited Inhibiteurs de kinases apparentés à la tropomyosine
US9163021B2 (en) 2012-10-04 2015-10-20 Pfizer Limited Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
CA2885253A1 (fr) 2012-10-04 2014-04-10 Pfizer Limited Inhibiteurs de kinase associee a la tropomyosine pyrrolo[2,3-d]pyrimidine
US9630896B2 (en) 2013-11-22 2017-04-25 Tansna Therapeutics, Inc. 2,5-dialkyl-4-H/halo/ether-phenol compounds
WO2017007755A1 (fr) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. N-aminophényl-amides hétérocycliques en tant qu'inhibiteurs de l'histone désacétylase
JP6936796B2 (ja) 2015-07-06 2021-09-22 ロダン・セラピューティクス，インコーポレーテッド ヒストンデアセチラーゼのヘテロハロ阻害剤
WO2018129403A1 (fr) 2017-01-06 2018-07-12 Yumanity Therapeutics Méthodes de traitement de troubles neurologiques
AU2018207402B2 (en) 2017-01-11 2023-09-28 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
CN110799503B (zh) 2017-06-30 2023-06-27 美国安进公司 美卡奥美坎替的合成
WO2019032528A1 (fr) 2017-08-07 2019-02-14 Rodin Therapeutics, Inc Inhibiteurs bicycliques d'histone désacétylase
US12023332B2 (en) 2018-03-05 2024-07-02 Wylder Nation Foundation Compositions and methods for activating signaling through the CB1 cannabinoid receptor for treating and preventing diseases and disorders characterized by abnormal cellular accumulation of sphingolipids such as sphingomyelin
EA039850B1 (ru) * 2018-04-30 2022-03-21 Эмджен Инк. Синтез омекамтива мекарбила
CN110437205B (zh) * 2018-08-24 2022-07-08 广东东阳光药业有限公司 吡啶烯基哌啶衍生物及其用途
EA202192047A1 (ru) * 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
CA3227681A1 (fr) * 2021-08-04 2023-02-09 Kimberly BABSON Methode de traitement d'un trouble de stress post-traumatique
EP4554674A1 (fr) * 2022-07-15 2025-05-21 Jazz Pharmaceuticals Ireland Limited Composés de biaryl-éther-urée utiles comme inhibiteurs de la faah
WO2024167423A1 (fr) 2023-02-07 2024-08-15 Captor Therapeutics S.A. Composés de dégradation de gspt1
US12410137B2 (en) 2023-07-17 2025-09-09 Apogee Pharmaceuticals, Inc. Fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB138405A (en) 1919-01-16 1920-02-12 Thomas Thompson Improvements in or relating to suction or delivery valves for pumps
GB1138405A (en) 1966-12-28 1969-01-01 Ici Ltd Morpholine derivatives
US3576810A (en) 1968-06-20 1971-04-27 Robins Co Inc A H 1-substituted-3-(-4)-aroylpiperidines
GB1260886A (en) 1969-06-20 1972-01-19 Ici Ltd Process for aryloxymethylmorpholine derivatives
BE758766A (fr) 1969-11-17 1971-05-10 Ici Ltd Nouveaux derives de la morpholine et de la
BE759013R (fr) 1969-11-17 1971-05-17 Ici Ltd Derives de la
US4116665A (en) 1976-04-02 1978-09-26 Eli Lilly And Company Method of regulating the growth of aquatic weeds with pyridine derivatives
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
GB8424979D0 (en) 1984-10-03 1984-11-07 Wyeth John & Brother Ltd Benzenesulphonamide derivatives
GB2167407B (en) 1984-11-22 1988-05-11 Erba Farmitalia Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
NZ246434A (en) 1991-12-18 1996-02-27 Schering Corp Imidazoylalkyl substituted by a six membered nitrogen containing heterocycle; pharmaceutical compositions and preparatory methods
DE4326344A1 (de) 1993-08-05 1995-02-09 Thomae Gmbh Dr K Carbonamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO1995006037A1 (fr) 1993-08-27 1995-03-02 Vrije Universiteit Nouveaux derives d'imidazoles a activite agoniste ou antagoniste du recepteur h3 a l'histamine
JP2978967B2 (ja) 1995-01-11 1999-11-15 三進製藥株式會社 新規ピペラジン誘導体、その製造方法及びそれを含有する組成物
US6271015B1 (en) 1995-06-12 2001-08-07 The Scripps Research Institute Fatty-acid amide hydrolase
GB9526560D0 (en) 1995-12-27 1996-02-28 Bayer Ag Use of 2-Amino-Heterocycles
FR2744449B1 (fr) 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6207665B1 (en) 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
US6184242B1 (en) 1997-09-04 2001-02-06 Syntex Usa (Llc) 2-(substituted-phenyl)amino-imidazoline derivatives
SK284468B6 (sk) 1998-04-01 2005-04-01 Janssen Pharmaceutica N. V. Pyridínový derivát, spôsob jeho prípravy a použitie, kompozícia s jeho obsahom a spôsob jej prípravy
EP1308443B1 (fr) 1998-12-29 2009-04-29 Pharmacia & Upjohn Company LLC Procédé pour la préparation d'éthers d'aryliques
PE20001566A1 (es) 1999-03-26 2001-02-05 Ucb Sa Piperazinas 1,4-sustituidas, piperidinas 1,4-sustituidas y 4-alquilidenilpiperidinas 1-sustituidas
ES2255490T3 (es) 1999-03-31 2006-07-01 Janssen Pharmaceutica N.V. Almidon pregelatinizado en una formulacion de liberacion controlada.
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
EP1227090A4 (fr) 1999-10-07 2002-11-20 Tadeka Chemical Ind Ltd Derives d'amines
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
KR20020063934A (ko) 2000-01-18 2002-08-07 화이자 프로덕츠 인코포레이티드 코르티코트로핀 방출 인자 길항제
HUP0301391A3 (en) 2000-02-11 2010-03-29 Vertex Pharma Piperazine and piperidine derivatives pharmaceutical compositions containing them and their use
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6552036B2 (en) 2000-03-03 2003-04-22 Ortho-Mcneil Pharmaceutical, Inc. 3-(Diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives
JP2001303987A (ja) 2000-04-21 2001-10-31 Toyota Motor Corp 筒内噴射式内燃機関のスロットル制御装置
AU2001264376A1 (en) 2000-06-15 2001-12-24 Chaconne Nsi Co., Ltd. Urea derivative useful as an anti-cancer agent and process for preparing same
US20020183316A1 (en) 2000-10-27 2002-12-05 Kevin Pan Amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
CA2437353A1 (fr) 2001-02-08 2002-08-15 Nps Pharmaceuticals, Inc. Procedes et composes pour le traitement de troubles neurologiques ou neuropsychiatriques, et procedes relatifs a l'identication de composes visant a traiter ces troubles
WO2003006447A2 (fr) 2001-07-09 2003-01-23 Pharmacia Italia Spa Inhibiteurs d'interaction de tcf-4 avec de la beta-catenine
AU2002363236A1 (en) 2001-10-30 2003-05-12 Millennium Pharmaceuticals, Inc. Compounds, pharmaceutical compositions and methods of use therefor
US20040034101A1 (en) 2001-11-05 2004-02-19 Cypress Bioscience, Inc. Treatment and prevention of depression secondary to pain (DSP)
JP3865626B2 (ja) 2001-11-08 2007-01-10 株式会社ベステックスキョーエイ パイプ部材
FR2833261B1 (fr) 2001-12-06 2004-07-02 Yang Ji Chemical Company Ltd Nouveaux composes inhibiteurs specifiques de la phospholipase a2 secretee non pancreatique humaine du groupe ii
US20040063726A1 (en) 2002-02-08 2004-04-01 Artman Linda D Methods and compounds for treating neurologic or neuropsychiatric disorders and identifying compounds to treat the same
AU2003218736B2 (en) 2002-03-13 2009-01-08 Janssen Pharmaceutica N.V. New inhibitors of histone deacetylase
US6995144B2 (en) 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
AU2003220184A1 (en) 2002-03-20 2003-10-08 Schering Aktiengesellschaft Substituted piperazine antithrombotic pai-1 inhibitors
TWI283241B (en) 2002-05-29 2007-07-01 Tanabe Seiyaku Co Novel piperidine compound
EP1572311A4 (fr) 2002-10-21 2007-12-12 Janssen Pharmaceutica Nv Analyse destinee a determiner l'activite de l'hydrolase des amides d'acides gras
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
KR20050118708A (ko) 2003-04-03 2005-12-19 메르크 파텐트 게엠베하 혈전-색전 질환의 치료에서 응고 인자 ｘａ의 저해제로서사용하기 위한피롤리디노-１,２-디카르복시-１-(페닐아미드)-２-(４-(３-옥소-모르폴리노-４-일)-페닐아미드) 유도체 및 관련화합물
SE0301442D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations therof and uses thereof
SE0301443D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
GB0325287D0 (en) 2003-10-29 2003-12-03 Merck Sharp & Dohme Therapeutic agents
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
ES2578254T3 (es) * 2003-12-03 2016-07-22 Ym Biosciences Australia Pty Ltd Inhibidores de cinasas basados en azol
WO2005075472A1 (fr) 2004-02-03 2005-08-18 Janssen Pharmaceutica, N.V. Derives de 3-(diheteroarylnethylene)-8-azabicyclo[3.2.1]octane et de 3-(aryl)(heteroaryl)methylene)-8-azabicyclo[3.2.1]octane
AU2005233569B2 (en) * 2004-04-09 2010-08-19 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
US20080103209A1 (en) 2004-04-23 2008-05-01 The Regents Of The University Of California Compounds And Methods For Treating Non-Inflammatory Pain Using Ppar Alpha Agonists
SE0401343D0 (sv) 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds: Pyridine N oxide as scaffold
PT1756084E (pt) 2004-06-04 2009-02-17 Arena Pharm Inc Composto seleccionado de compostos de fórmula (i) e seus sais, solvatos, hidratos e n-óxidos farmaceuticamente aceitáveis
DE102004039789A1 (de) 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2316458A1 (fr) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Derives de pyridazine destines a l'inhibition du desaturase-coa-stearoyl de l'humain
DE102004045796A1 (de) 2004-09-22 2006-03-23 Merck Patent Gmbh Arzneimittel enthaltend Carbonylverbindungen sowie deren Verwendung
US20090105221A1 (en) 2004-09-29 2009-04-23 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
US7491720B2 (en) 2004-10-29 2009-02-17 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives having Aurora A selective inhibitory action
EP1657241A1 (fr) 2004-11-03 2006-05-17 Schering Aktiengesellschaft Nouveaux urées d' anthranylamide pyridine ayant une activité inhibitrice de kinase du récepteur de VEGF
EP1655297A1 (fr) 2004-11-03 2006-05-10 Schering Aktiengesellschaft Pyridineurées de nicotinamide commes inhibiteurs du recepteur kinase du facteur de croissance endothéliale vasculaire (VEGF)
TW200633990A (en) 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound
GT200500375A (es) 2004-12-20 2006-11-28 Derivados de piperidina y su uso como agentes antiinflamatorios
EP1838311A1 (fr) 2004-12-24 2007-10-03 Prosidion Limited Agonistes du récepteur couplé aux protéines g (gpr116) et leur emploi dans le traitement de l'obésité et du diabète
EP1831164A1 (fr) 2004-12-24 2007-09-12 AstraZeneca AB Composés hétérocycliques en tant qu'antagonistes de ccr2b
EP2937341B1 (fr) * 2004-12-30 2017-07-05 Janssen Pharmaceutica N.V. Dérivés d'phénylamides de 4-(benzyl)-pipérazine-1-acide carboxylique et composés similaires en tant que modulateurs de l'hydrolase des amides d'acides gras (faah) pour le traitement de l'anxiété, de la douleur et d'autres états
CA2597131A1 (fr) 2005-02-10 2006-08-17 Warner-Lambert Company Llc Analyse d'hydrolase d'amide d'acide gras
ATE481407T1 (de) * 2005-02-16 2010-10-15 Neurosearch As Neue diazabicyclische arylderivate und medizinische verwendung dafür
US7919495B2 (en) 2005-02-17 2011-04-05 Astellas Pharma, Inc. Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound
US20090082435A1 (en) 2005-04-28 2009-03-26 The Regents Of The University Of California Methods, Compositions, And Compounds For Modulation Of Monoacylglycerol Lipase, Pain, And Stress-Related Disorders
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
WO2006129842A1 (fr) 2005-06-01 2006-12-07 Banyu Pharmaceutical Co., Ltd. Nouveau derive aminopyridine ayant une activite d’inhibition selective de l’aurora-a
WO2006137465A1 (fr) 2005-06-24 2006-12-28 Shionogi & Co., Ltd. Dérivé hétérocyclique azoté
BRPI0613505A2 (pt) 2005-06-30 2011-01-11 Prosidion Ltd agonistas de gpcr
US7541359B2 (en) 2005-06-30 2009-06-02 Janssen Pharmaceutica N.V. N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase
CA2621164A1 (fr) 2005-08-26 2007-03-01 Shionogi & Co., Ltd. Derive ayant une activite agoniste vis-a-vis du ppar
US7131609B1 (en) 2005-08-31 2006-11-07 Kimberly-Clark Worldwide, Inc. Dispenser for sheet material
US20070155707A1 (en) 2005-12-29 2007-07-05 Kadmus Pharmaceuticals, Inc. Ionizable inhibitors of fatty acid amide hydrolase
MX2008008529A (es) 2005-12-29 2008-09-26 Organon Nv Inhibidores de amida hidrolasa de acido graso.
WO2007103456A2 (fr) 2006-03-06 2007-09-13 Trimeris, Inc. Derives de piperazine et piperidine biaryle
TW200811157A (en) * 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators I
WO2008005368A2 (fr) 2006-06-30 2008-01-10 Abbott Laboratories Pipérazines en tant qu'antagonistes de p2x7
WO2008024139A2 (fr) 2006-08-18 2008-02-28 N.V. Organon Inhibiteurs d'hydrolase des amides d'acides gras
EP2054055A2 (fr) 2006-08-18 2009-05-06 N.V. Organon Inhibiteur de faah et agent analgésique, anti-inflammatoire ou anti-pyrétique combinés
US7888394B2 (en) 2006-08-21 2011-02-15 N.V. Organon Synthesis, polymorphs, and pharmaceutical formulation of FAAH inhibitors
EP2065369A4 (fr) 2006-08-23 2011-12-28 Astellas Pharma Inc Compose d'uree ou sel dudit compose
US20080089845A1 (en) 2006-09-07 2008-04-17 N.V. Organon Methods for determining effective doses of fatty acid amide hydrolase inhibitors in vivo
US20090099240A1 (en) 2006-10-02 2009-04-16 N.V. Organon Methods for treating energy metabolism disorders by inhibiting fatty acid amide hydrolase activity
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
RS20090154A (sr) 2006-10-18 2010-10-31 Pfizer Products Inc. Jedinjenja biaril etra uree
WO2008063714A1 (fr) 2006-11-20 2008-05-29 N.V. Organon Inhibiteurs stabilisés métaboliquement d'hydrolase d'amides d'acide gras
NZ552238A (en) 2006-12-20 2009-07-31 Seperex Nutritionals Ltd An extract
JP2010528114A (ja) 2007-05-25 2010-08-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 脂肪酸アミド加水分解酵素のヘテロアリール置換尿素モジュレータ

Also Published As

Publication number Publication date
HK1139652A1 (en) 2010-09-24
HN2007000407A (es) 2010-10-04
CL2007003000A1 (es) 2008-06-13
UY30649A1 (es) 2008-05-31
BRPI0717596B8 (pt) 2021-05-25
BRPI0717596B1 (pt) 2020-04-14
AU2007311591A1 (en) 2008-04-24
CA2663984A1 (fr) 2008-04-24
WO2008047229A2 (fr) 2008-04-24
ATE493984T1 (de) 2011-01-15
ME01308B (me) 2013-12-20
KR101181194B1 (ko) 2012-09-18
PL2076508T3 (pl) 2011-05-31
KR20090061051A (ko) 2009-06-15
ZA200902548B (en) 2010-03-31
CR20140313A (es) 2014-07-28
NO20091560L (no) 2009-05-15
PT2076508E (pt) 2011-03-07
CN101595102A (zh) 2009-12-02
IL197664A (en) 2013-01-31
NZ575624A (en) 2012-02-24
US8044052B2 (en) 2011-10-25
EA200970296A1 (ru) 2009-10-30
JP4434313B2 (ja) 2010-03-17
EA015488B1 (ru) 2011-08-30
IL197664A0 (en) 2009-12-24
TW200825062A (en) 2008-06-16
ES2357340T3 (es) 2011-04-25
HRP20110158T1 (hr) 2011-04-30
MY145460A (en) 2012-02-15
MA30801B1 (fr) 2009-10-01
US20080261941A1 (en) 2008-10-23
CN101595102B (zh) 2013-08-07
EP2076508B1 (fr) 2011-01-05
AP2780A (en) 2013-09-30
JP2010506896A (ja) 2010-03-04
AU2007311591B2 (en) 2010-10-07
CY1111170T1 (el) 2015-06-11
TWI404715B (zh) 2013-08-11
MX2009004233A (es) 2009-08-12
BRPI0717596A2 (pt) 2013-10-29
DE602007011793D1 (de) 2011-02-17
RS51647B (sr) 2011-10-31
CR10701A (es) 2009-04-30
NO342266B1 (no) 2018-04-30
SI2076508T1 (sl) 2011-04-29
PE20081265A1 (es) 2008-09-17
CA2663984C (fr) 2012-02-21
AP2009004821A0 (en) 2009-04-30
DK2076508T3 (da) 2011-02-21
WO2008047229A3 (fr) 2008-09-04
RS20090154A (sr) 2010-10-31
AR063331A1 (es) 2009-01-21
GEP20125425B (en) 2012-03-26
EP2076508A2 (fr) 2009-07-08

Similar Documents

Publication Publication Date Title
TN2009000138A1 (fr) Biaryl-ether-urees
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
TNSN07022A1 (fr) Derives de pyridine
MA29926B1 (fr) Derives de pyrazine
TN2010000175A1 (fr) Piperidino-dihydrothienopyrimidines substituees
TNSN08445A1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
MA30289B1 (fr) Dérivés d'amines
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
TNSN04151A1 (fr) Derives de nicotinamide utiles comme inhibiteurs de pde4
MA31894B1 (fr) Composes organiques
MA26697A1 (fr) Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant
TN2009000450A1 (fr) Derives de pyridine
TNSN99095A1 (fr) 4 - phenylpiperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA30403B1 (fr) Derives d'acides cycloalkylamines et leurs compositions pharmaceutiques
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
MA31373B1 (fr) Composes amino-heterocycliques
MA32009B1 (fr) Nouveaux derives de pyrazolo [3,4-d]pyrimidine en tant qu'agents anticancereux
TNSN08270A1 (fr) Dérivés pyrimidiques destinés à traiter une croissance cellulaire anormale
TNSN99031A1 (fr) Composes heterocycliques nouveaux inhibiteurs de romatases, procede pour leur preparation et compositions pharmaceutiques les contenant
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
MA31919B1 (fr) Composés inhibiteurs de la dipeptidyl peptidase-iv, leurs procédés de préparation, et compositions pharmaceutiques contenant ces composés comme agent actif
TNSN05073A1 (fr) Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase
MA29411B1 (fr) 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa
MA30313B1 (fr) Amines secondaires en tant qu'inhibiteurs de la renine
MA31761B1 (fr) Nouveaux inhibiteurs de seh et leur utilisation